Table 1.
Baseline Characteristics by Treatment Arm in the PROVE IT‐TIMI 22 Trial
| Characteristic | Atorvastatin 80 mg QD (n=2063) | Pravastatin 40 mg QD (n=2099) |
|---|---|---|
| Age, y (mean±SD) | 58.1±11.2 | 58.3±11.3 |
| Male | 77.9% | 78.4% |
| White race | 91.0% | 90.5% |
| Diabetes mellitus | 17.8% | 17.5% |
| Hypertension | 51.3% | 49.2% |
| History of renal failure | 8.82% | 9.14% |
| Serum creatinine (mean±SD, mg/dL) | 1.03±0.25 | 1.04±0.24 |
| eGFR (mean±SD, mL/min per 1.73 m2) | 80.0±20.1 | 79.0±19.1 |
| PCI for qualifying event | 69.1% | 68.7% |
| ACE‐I or ARB at randomization | 60.4% | 62.4% |
| Baseline CKD stage, mL/min per 1.73 m2 | ||
| eGFR ≥90 | 29.43% | 26.53% |
| 60 to <90 | 56.18% | 59.07% |
| 30 to <60 | 14.11% | 14.02% |
| 15 to <30 | 0.27% | 0.39% |
| <15 | 0.00% | 0.00% |
ACE‐I indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention; PROVE IT‐TIMI 22, Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22.